Drug delivery carriers on the fringes: Natural red blood cells versus synthetic multilayered capsules

Expert Opinion on Drug Delivery

Volumn 10, Issue 1, 2013, Pages 1-4

  Muzykantov, Vladimir R ^a  

^a University of Pennsylvania   (United States)

Author keywords

Biocompatibility; Polymeric carriers; Red blood cells; Sustained drug delivery

Indexed keywords

ANTITHROMBOCYTIC AGENT; DRUG CARRIER; NANOCARRIER; POLYPEPTIDE; THROMBIN;

BIOCOMPATIBILITY; BIOLOGICAL THERAPY; CONTROLLED RELEASE FORMULATION; COST; DRUG CAPSULE; DRUG DELIVERY SYSTEM; ENCAPSULATION; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; ERYTHROCYTE VOLUME; IMAGING; NATURAL RED BLOOD CELL; REVIEW; RISK; SYNTHETIC MULTILAYERED CAPSULE;

BIOLOGICAL AGENTS; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; HUMANS; LIPOSOMES;

EID: 84871431260     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.750292     Document Type: Review

References (19)

1. Kolesnikova TA, Skirtach AG, Mohwald H. Red blood cells and polyelectrolyte multilayer capsules: natural carriers versus polymer-based drug delivery vehicles. Exp Opin Drug Deliv 2013;10(1):47-58
2. Delcea M, Sternberg N, Yashchenok AM, et al. Nanoplasmonics for dual-molecule release through nanopores in the membrane of red blood cells. ACS Nano 2012;6(5):4169-80
3. Hu CM, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011;108(27):10980-5
4. Luo R, Mutukumaraswamy S, Venkatraman SS, Neu B. Engineering of erythrocyte-based drug carriers: control of protein release and bioactivity. J Mater Sci Mater Med 2012;23(1):63-71
5. Ariga K, Ji Q, Hill JP, et al. Forming nanomaterials as layered functional structures toward materials nanoarchitectonics. NPG Asia Materials 2012;4:e17
6. Lee KJ, Yoon J, Rahmani S, et al. Spontaneous shape reconfigurations in multicompartmental microcylinders. Proc Natl Acad Sci USA 2012;109(40):16057-62
7. Sternberg N, Georgieva R, Duft K, Baumler H. Surface-modified loaded human red blood cells for targeting and delivery of drugs. J Microencapsul 2012;29(1):9-20
8. Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci USA 1973;70(9):2663-6
9. Magnani M, Pierige F, Rossi L. Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. Ther Deliv 2012;3(3):405-14
10. Cinti C, Taranta M, Naldi I, Grimaldi S. Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds. PLoS ONE 2011;6(2):e17132
11. Orekhova NM, Akchurin RS, Belyaev AA, et al. Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. Thromb Res 1990;57(4):611-16 (Pubitemid 20110426)
12. Muzykantov VR, Sakharov DV, Smirnov MD, et al. Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot. Biochim Biophys Acta 1986;884(2):355-62 (Pubitemid 17188780)
13. Muro S, Garnacho C, Champion JA, et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 2008;16(8):1450-8
14. Shuvaev VV, Ilies MA, Simone E, et al. Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano 2011;5(9):6991-9
15. Simone EA, Dziubla TD, Muzykantov VR. Polymeric carriers: role of geometry in drug delivery. Expert Opin Drug Deliv 2008;5(12):1283-300
16. Merkel TJ, Jones SW, Herlihy KP, et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA 2011;108(2):586-91
17. Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7(4):403-27
18. Colin FC, Schrier SL. Spontaneous endocytosis in human neonatal and adult red blood cells: comparison to drug-induced endocytosis and to receptor-mediated endocytosis. Am J Hematol 1991;37(1):34-40
19. Zaitsev S, Spitzer D, Murciano JC, et al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood 2010;115(25):5241-8